SG Americas Securities LLC Grows Stake in Charles River Laboratories International, Inc. $CRL

SG Americas Securities LLC raised its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 2.4% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 186,173 shares of the medical research company’s stock after purchasing an additional 4,395 shares during the period. SG Americas Securities LLC’s holdings in Charles River Laboratories International were worth $32,115,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of the stock. Purpose Unlimited Inc. bought a new position in Charles River Laboratories International during the 4th quarter valued at about $698,000. Rockefeller Capital Management L.P. lifted its stake in Charles River Laboratories International by 30.0% in the fourth quarter. Rockefeller Capital Management L.P. now owns 1,750 shares of the medical research company’s stock worth $349,000 after purchasing an additional 404 shares during the last quarter. Eos Management L.P. bought a new stake in Charles River Laboratories International in the fourth quarter worth about $839,000. Corient Private Wealth LLC boosted its position in shares of Charles River Laboratories International by 68.5% during the fourth quarter. Corient Private Wealth LLC now owns 17,628 shares of the medical research company’s stock valued at $3,516,000 after buying an additional 7,166 shares during the period. Finally, SHP Wealth Management bought a new position in shares of Charles River Laboratories International during the fourth quarter valued at approximately $85,000. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Morgan Stanley upgraded Charles River Laboratories International from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $185.00 to $220.00 in a report on Wednesday, June 17th. Barclays upped their price objective on Charles River Laboratories International from $210.00 to $220.00 and gave the company an “overweight” rating in a research report on Friday, May 8th. Evercore reiterated an “outperform” rating and issued a $220.00 target price on shares of Charles River Laboratories International in a research note on Friday, May 8th. CLSA raised shares of Charles River Laboratories International from a “hold” rating to an “outperform” rating and boosted their target price for the company from $167.00 to $219.00 in a research note on Friday, May 29th. Finally, JPMorgan Chase & Co. cut their price target on shares of Charles River Laboratories International from $165.00 to $160.00 and set a “neutral” rating on the stock in a report on Monday, April 13th. Twelve investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $211.00.

Charles River Laboratories International Trading Up 2.5%

NYSE:CRL opened at $186.08 on Wednesday. Charles River Laboratories International, Inc. has a one year low of $144.26 and a one year high of $228.88. The company has a debt-to-equity ratio of 0.90, a quick ratio of 1.03 and a current ratio of 1.36. The firm has a market cap of $8.96 billion, a P/E ratio of -49.49, a P/E/G ratio of 2.07 and a beta of 1.46. The firm has a 50-day simple moving average of $175.14 and a 200-day simple moving average of $182.81.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Thursday, May 7th. The medical research company reported $2.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.96 by $0.10. The firm had revenue of $995.83 million for the quarter, compared to the consensus estimate of $977.46 million. Charles River Laboratories International had a negative net margin of 4.59% and a positive return on equity of 15.36%. The company’s quarterly revenue was up 1.2% on a year-over-year basis. During the same period last year, the firm earned $2.34 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 10.800-11.300 EPS. Equities analysts anticipate that Charles River Laboratories International, Inc. will post 11.05 EPS for the current fiscal year.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.